Mumbai-based Aglowmed Ltd has launched Vensy, an exclusive respiratory antioxidant for the first time in India. It claims to have beneficial effects in diseases and infections that directly or indirectly put the free radical burden on lung tissues. Vensy combines N-Acetylcysteine (200mg) and Ambroxol (30mg) in capsule form.

"Vensy has a definite therapeutic role in tuberculosis, COPD and HIV cases. Vensy is to be taken along with anti-infective drugs during cases of lung infections like TB. The bacterial infection erodes away the tissues of lungs and malfunctions them. Vensy's role would be to control this effect," said T. Lakshmoji, senior product manager, Aglowmed.

"Multiple-drug anti-Kochs therapy (AKT), low bioavailability of rifampicin-isoniazid combinations, high overages and long-term medication; all put together complicate the anti-TB therapy. We felt Vensy could facilitate safer anti-TB therapy, and being a respiratory-specific antioxidant with anti-inflammatory, immunomodulator and mucolytic/mucokinetic properties, its coadminstration with standard AKT regimens will minimize tissue damage," he added.

Dr. R. K. Sanghavi, Medical Advisor of Aglowmed said "Vensy has the beneficial therapeutic role in many front-line respiratory ailments including the killer infectious disease pulmonary tuberculosis". He further added, "N-Acetylecysteine and and ambroxol are both proven and time-tested agents and their combination as Vensy is a logical addition to the existing AKT regimens in order to reduce complications of TB drugs as well as protecting the vital respiratory tissues. Further, Vensy has the beneficial effect on liver and lung functioning which are of high importance in TB cases."

Lakshmoji maintained that Vensy is affordably priced so that the poor segments of the society could avail of the benefits offered by the drug.